{"chunk_type":"transcript_chunk","text":"# Pituitary Hyperfunction Core: Prolactinoma First-pass Framework\n## Clinical pattern by population\n| 환자군 | 주요 단서 | 임상 의미 |\n| --- | --- | --- |\n| Premenopausal women | amenorrhea/oligomenorrhea, infertility, galactorrhea | hypogonadism 및 bone loss 위험 |\n| Men/postmenopausal women | headache, bitemporal visual loss 등 mass effect | 대개 macroadenoma로 늦게 발견 |\n\n## Diagnostic order\n- prolactin이 매우 높아도 mimics(약물, 임신, hypothyroidism, renal failure) 배제가 선행.\n- TSH/creatinine/pregnancy status 확인 후 pituitary MRI로 진행.\n\n## Core principle\n- Step 2에서는 \"수치 확인 -> 원인 분기 -> 영상\" 순서를 지키는지가 점수 포인트.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-1","focus_area":"Pituitary Prolactinoma Framework","tags":["usmle-step2","endocrinology","pituitary","prolactinoma","diagnosis","table"]}
{"chunk_type":"transcript_chunk","text":"# Prolactinoma Treatment + Acromegaly + SIADH/DI Entry\n## Prolactinoma treatment\n- 1차 치료는 dopamine agonist(cabergoline 선호)이며 수술은 약물 실패/긴급 압박 상황에서 고려.\n\n## Acromegaly logic\n- IGF-1로 스크리닝, oral glucose suppression failure로 확진, 이후 수술 중심 치료.\n- 합병증(심혈관, OSA, 당대사, 대장병변) 동시 평가 필요.\n\n## SIADH basics\n- euvolemic hyponatremia 패턴, 원인(CNS/lung/drug) 추적.\n- 중증 증상에서는 hypertonic saline을 신중한 교정 속도로 사용.\n\n## DI vs primary polydipsia entry\n- 핵심 분기: free-water loss 여부와 serum sodium 방향.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-21","focus_area":"Prolactinoma Acromegaly SIADH DI","tags":["usmle-step2","endocrinology","acromegaly","siadh","di","treatment"]}
{"chunk_type":"transcript_chunk","text":"# Hypopituitarism + Primary vs Secondary Adrenal Insufficiency + Pituitary Recap\n## Hypopituitarism\n- 종양 압박, apoplexy, postpartum ischemia(Sheehan), 침윤성 질환이 주요 원인.\n- 다축 호르몬 결핍 패턴을 구조적으로 확인.\n\n## Primary vs Secondary adrenal insufficiency table\n| 항목 | Primary AI (Adrenal) | Secondary AI (Pituitary/Hypothalamic) |\n| --- | --- | --- |\n| Aldosterone | 감소 가능 | 대개 보존 |\n| Potassium | 상승 경향 | 대체로 정상 |\n| ACTH/pigmentation | ACTH 상승, hyperpigmentation 가능 | ACTH 낮음, pigmentation 없음 |\n| 임상 단서 | salt craving/volume depletion | 다른 pituitary axis 결핍 동반 가능 |\n\n## Pituitary rapid recap\n- prolactinoma는 mimic exclusion 후 접근.\n- acromegaly는 IGF-1 -> suppression test -> 수술 순서.\n- SIADH/DI는 sodium과 volume 맥락으로 감별.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-41","focus_area":"Hypopituitarism and Adrenal Differential","tags":["usmle-step2","endocrinology","hypopituitarism","adrenal-insufficiency","table"]}
{"chunk_type":"transcript_chunk","text":"# Primary Hyperparathyroidism vs FHH Framework\n## Primary hyperparathyroidism\n- 고칼슘혈증 + 부적절하게 높거나 억제되지 않은 PTH 조합이 핵심.\n- 무증상 발견이 흔하며 renal/bone 합병증 risk를 병행 평가.\n\n## FHH differentiation\n| 항목 | Primary hyperparathyroidism | FHH |\n| --- | --- | --- |\n| Serum calcium | 상승 | 경도 상승 |\n| PTH | 상승 또는 inappropriately normal | 정상~경도 상승 |\n| Urine calcium excretion | 상대적으로 높음 | 낮음 (Ca/Cr clearance ratio 낮음) |\n| 치료 전략 | 수술 고려 가능 | 수술 비권장(보존적 관리) |\n\n## Step 2 pearl\n- parathyroid surgery 전 FHH 배제는 필수 안전 단계.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-61","focus_area":"Primary Hyperparathyroidism vs FHH","tags":["usmle-step2","endocrinology","hyperparathyroidism","fhh","diagnosis","table"]}
{"chunk_type":"transcript_chunk","text":"# Neonatal Hypocalcemia (Maternal FHH Context) + Parathyroid Surgery Indications + CKD Progression\n## Neonatal scenario\n- maternal hypercalcemia 환경에서 fetal parathyroid suppression 발생 후 출생 직후 저칼슘 발작 가능.\n- supportive calcium/vitamin D bridge가 핵심.\n\n## Surgery indications in primary hyperparathyroidism\n- symptomatic disease는 수술 우선.\n- asymptomatic에서도 연령, calcium burden, renal function/stones, bone density/fracture, urine calcium 기준으로 수술 고려.\n\n## Secondary/Tertiary hyperparathyroidism\n- CKD에서 phosphate retention + calcitriol 저하로 secondary hyperPTH.\n- 장기화 시 autonomous tertiary 상태로 전환 가능하며 severe mineral complication 동반.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-81","focus_area":"Neonatal Hypocalcemia and HyperPTH Surgery Rules","tags":["usmle-step2","endocrinology","neonatal","hyperparathyroidism","surgery"]}
{"chunk_type":"transcript_chunk","text":"# Calciphylaxis + Post-surgical Hypoparathyroidism + Calcium-Phosphate Product Safety\n## Calciphylaxis\n- CKD/고칼슘-고인산 환경에서 vascular calcification으로 피부 괴사/고통/높은 사망률.\n- severe refractory case는 parathyroid intervention까지 고려.\n\n## Post-op hypoparathyroidism\n- neck surgery 이후 hypocalcemia 관리에서 calcium + active vitamin D 보충.\n\n## Calcium-phosphate product target\n- 연조직/기저핵 석회화 위험을 줄이기 위해 Ca x P product 과상승을 피한다.\n- 단순 칼슘 보충이 아니라 phosphate control과 균형 관리가 중요.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-101","focus_area":"Calciphylaxis and Post-op Hypoparathyroidism","tags":["usmle-step2","endocrinology","calciphylaxis","hypoparathyroidism","safety"]}
{"chunk_type":"transcript_chunk","text":"# Endocrine Decision Framework: Pituitary, Thyroid, Parathyroid, Adrenal, Diabetes\n## Core tree principle\n- 진단명 암기보다 next-best-step 분기(먼저 배제할 것, 먼저 측정할 것, 먼저 치료할 것)를 고정한다.\n\n## Pituitary water-balance table\n| 구분 | 병태생리 포인트 | 혈청 Na 경향 |\n| --- | --- | --- |\n| Primary polydipsia | 과도한 물 섭취 | 낮아지기 쉬움 |\n| Central DI | ADH 결핍으로 자유수분 소실 | 높아지기 쉬움 |\n| Nephrogenic DI | ADH resistance, 보상적 음수 시 Na가 덜 상승 | 정상~상승 |\n\n## Thyroid/parathyroid/adrenal integration\n- 임신, 노인, 중환자 컨텍스트가 같은 수치라도 처치를 바꾸는 핵심 변수.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-121","focus_area":"Cross-Endocrine Decision Framework","tags":["usmle-step2","endocrinology","decision-tree","di","thyroid","table"]}
{"chunk_type":"transcript_chunk","text":"# Thyroid in Pregnancy + Nodule + Hyperaldosteronism + Adrenal Insufficiency Integration\n## Thyroid in pregnancy\n- 생리적 TBG/hCG 변화와 진성 갑상선 질환을 구분.\n- hypothyroidism 임신에서는 빠른 hormone dose adjustment가 fetal neurodevelopment에 중요.\n\n## Thyroid nodule algorithm\n- TSH 기반으로 scintigraphy 필요군과 ultrasound/FNA 중심군을 분리.\n\n## Hyperaldosteronism\n- resistant HTN + hypokalemia에서 ARR 선별 후 subtype 분류.\n\n## Adrenal insufficiency\n- hyponatremia/hyperkalemia/eosinophilia 패턴과 stress-state deterioration를 함께 본다.\n- adrenal crisis 의심 시 지연 없이 steroid + fluids.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-141","focus_area":"Thyroid Pregnancy and Adrenal Integration","tags":["usmle-step2","endocrinology","thyroid","pregnancy","adrenal","diagnosis"]}
{"chunk_type":"transcript_chunk","text":"# Diabetes Autonomic Failure + Gastroparesis + Thyroid Gray-zone Management\n## Hypoglycemia-associated autonomic failure\n- 반복 저혈당이 adrenergic warning 신호를 둔화시켜 severe unrecognized hypoglycemia 위험 증가.\n\n## Gastroparesis in diabetes\n- delayed gastric emptying으로 insulin-action/absorption mismatch가 발생해 postprandial glycemic variability를 유발.\n\n## Thyroid gray-zone pearls\n- subclinical hypothyroidism 치료 여부는 연령/TSH 수준/증상/리스크로 개별화.\n- euthyroid sick syndrome은 중증질환 적응반응 맥락에서 과치료를 피한다.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-161","focus_area":"Diabetes Autonomic Failure and Thyroid Gray Zones","tags":["usmle-step2","endocrinology","diabetes","gastroparesis","thyroid"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap + Endocrine Pharmacology Management Entry\n## Rapid endocrine recap\n1. prolactin elevation은 MRI 전에 mimic 배제가 우선.\n2. thyroid nodule은 TSH-first로 경로 분기.\n3. 임신 hypothyroidism은 조기 용량 조정이 중요.\n4. hypercalcemia에서 urine calcium으로 FHH를 배제.\n5. adrenal insufficiency 의심 시 지연 없는 평가/치료.\n6. 노인/중환자 thyroid 수치는 overtreatment를 피하는 판단이 중요.\n\n## Transition\n- 다음 파트는 endocrine pharmacology에서 환자군별 약제 선택/금기를 연결한다.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-171","focus_area":"Endocrine Rapid Recap and Pharm Entry","tags":["usmle-step2","endocrinology","recap","pharmacology","next-step"]}
{"chunk_type":"transcript_chunk","text":"# Pituitary/Thyroid Pharmacology Decisions + SIADH/DI Emergency Actions\n## Prolactinoma medication-first\n- macro lesion과 visual symptoms가 있어도 dopamine agonist를 우선 시도하는 것이 표준적 상황이 많다.\n\n## SIADH vs DI practical management\n- SIADH severe neurologic symptoms: 3% saline 포함 응급 교정.\n- DI는 desmopressin 사용 시 과교정/수분 과다 섭취를 함께 감시.\n\n## Graves treatment in pregnancy table\n| 시기 | 우선 약물 | 핵심 이유 |\n| --- | --- | --- |\n| 1분기 | PTU | 초기 태아 기형 위험 최소화 |\n| 2-3분기 | Methimazole | PTU 장기 간독성 위험 감소 |\n\n## Graves with ophthalmopathy\n- radioiodine가 eye disease 악화 가능해 약물/수술 전략을 우선 고려.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-181","focus_area":"Pituitary Thyroid Pharmacology Decisions","tags":["usmle-step2","endocrinology","graves","siadh","di","table"]}
{"chunk_type":"transcript_chunk","text":"# Thyroid Replacement Nuance + Adrenal and Parathyroid Safety Rules\n## Thyroid follow-up nuance\n- hyperthyroidism 치료 초기 추적은 TSH lag를 고려해 free hormone 중심으로 본다.\n- hypothyroidism replacement는 노인에서 저용량 시작 후 점진 증량.\n- 임신부는 확진 대기보다 조기 dose adjustment가 우선될 수 있음.\n\n## Adrenal/parathyroid safety\n- unilateral vs bilateral hyperaldosteronism 치료 분기를 구분.\n- septic physiology에서 adrenal reserve 저하 위험 약물(예: etomidate) 사용에 주의.\n- tertiary hyperparathyroidism/calcification risk는 mineral balance와 수술 적응증을 함께 판단.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-201","focus_area":"Thyroid Replacement and Adrenal Safety","tags":["usmle-step2","endocrinology","hypothyroidism","adrenal","parathyroid","treatment"]}
{"chunk_type":"transcript_chunk","text":"# Diabetes Maintenance + High-yield Scenario Recap + Thyroid Deep Dive Entry\n## Diabetes maintenance\n- foot neuropathy screening(monofilament)은 절단 위험 예방의 핵심.\n- 고령 당뇨 환자에서는 저혈당 피해를 줄이기 위한 완화된 A1c 목표가 합리적.\n\n## Scenario rapid checks\n- prolactinoma: meds first.\n- Graves + significant ophthalmopathy: RAI 회피.\n- pregnancy-specific thyroid management는 trimester context 반영.\n- severe hyponatremic symptoms에서는 제한적 처치보다 응급 교정 필요.\n\n## Transition to thyroid deep dive\n- 다음 학습 블록은 hyper/hypothyroidism과 nodule algorithm을 Step 2 관리 문제 관점으로 확장.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-221","focus_area":"Diabetes Maintenance and Thyroid Transition","tags":["usmle-step2","endocrinology","diabetes","recap","thyroid","next-step"]}
